Trial Profile
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months); With a Brief Evaluation of Executive Cognition
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2015
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 01 Feb 2009 Results published in the Journal of Clinical Psychopharmacology.
- 01 Feb 2009 Primary endpoint 'assessment scale scores' has been met.
- 27 Oct 2006 Status change